Tartarone Alfredo, Romano Giampiero, Galasso Rocco, Coccaro Mariarosa, Cammarota Aldo, Sgambato Alessandro, Bochicchio Annamaria
Department of Medical Oncology, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy.
Tumori. 2002 Mar-Apr;88(2):173-5. doi: 10.1177/030089160208800219.
There is an increased risk of cancer after organ transplantation mainly due to the immunosuppressive therapy required in these patients. We report a case of biphasic pulmonary blastoma in an adult male who underwent liver transplant for hepatocellular carcinoma in March 1999, followed by immunosuppressive treatment and adjuvant chemotherapy with epirubicin. Disease-free survival lasted 18 months, then a diagnosis of biphasic pulmonary blastoma was made and the patient underwent a lung lobectomy. Five months after surgical resection a recurrence of this rare tumor was recorded and two cycles of cisplatin + etoposide and ifosfamide + etoposide and one cycle of second-line chemotherapy with vinorelbine were administered. The tolerability and the efficacy of this treatment were poor. The patient died less than one year after diagnosis. To our knowledge this is the first reported case of pulmonary blastoma in a transplant patient. Our findings confirm that organ transplant recipients deserve long-term medical surveillance also in the absence of graft complications, and that pulmonary blastoma is an aggressive tumor with a poor prognosis.
器官移植后癌症风险增加,主要是因为这些患者需要进行免疫抑制治疗。我们报告一例成年男性双相性肺母细胞瘤病例,该患者于1999年3月因肝细胞癌接受肝移植,随后接受免疫抑制治疗及表柔比星辅助化疗。无病生存期持续了18个月,之后诊断为双相性肺母细胞瘤,患者接受了肺叶切除术。手术切除五个月后,记录到这种罕见肿瘤复发,给予两周期顺铂 + 依托泊苷及异环磷酰胺 + 依托泊苷治疗,并给予一周期长春瑞滨二线化疗。该治疗的耐受性和疗效较差。患者在诊断后不到一年死亡。据我们所知,这是移植患者中首例报告的肺母细胞瘤病例。我们的研究结果证实,器官移植受者即使没有移植物并发症也值得长期医学监测,且肺母细胞瘤是一种侵袭性肿瘤,预后较差。